Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 multicentre, open, parallel, prospective, randomized comparative clinical study of Dulaglutide Injection (BA5101) in Chinese adults with type 2 diabetes

Next Previous
Trial Profile

Phase 3 multicentre, open, parallel, prospective, randomized comparative clinical study of Dulaglutide Injection (BA5101) in Chinese adults with type 2 diabetes

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dulaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Shandong Boan Biotechnology

Most Recent Events

  • 08 Apr 2026 According to a Shandong Boan Biotechnology media release, the National Medical Products Administration (NMPA) has granted marketing approval to its Boyouping indicated for glycemic control in adults with type 2 diabetes mellitus. Boyouping is the first and only biosimilar to Trulicity approved for marketing in the world.
  • 28 May 2024 According to a Luye Pharma Group media release,the company has announced that the Center for Drug Evaluation (CDE) of Chinas National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for its Dulaglutide Injection (BA5101), a drug for glycemic control in adults with type 2 diabetes.
  • 15 May 2023 Status changed from recruiting to active, no longer recruiting according to Luye Pharma Group media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top